Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Insulin Degludec vs Insulin Glargine U300 in T1DM
NCT02536859Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2015
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin degludec in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the glucose infusion rate curve. Started Aug 2015; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02536859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536859.